abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

このページは 日本語 では利用できません。English で表示されています

記事

2015年3月20日

著者:
Karyn Kaplan, Director, International Hepatitis/HIV Policy & Advocacy, Treatment Action Group

Comment by Karyn Kaplan

全てのタグを見る

...Gilead is now forcing both doctors and patients in resource-limited settings to jump through unethical hoops before accessing low-cost versions of these drugs. A restrictive anti-diversion clause in their recent license to Indian generic producers forces clinicians to violate basic medical ethics and patient human rights by revealing confidential patient data....

タイムライン